Geneoscopy’s Novel Stool-Based RNA Platform Shows High Accuracy in Monitoring Crohn’s Disease
01 Agosto 2024 - 7:05AM
Business Wire
Geneoscopy, Inc., a life sciences company focused on developing
diagnostic tests for the advancement of gastrointestinal health,
announced the publication of a peer-reviewed study in Gastro Hep
Advances, highlighting the effectiveness of Geneoscopy’s
noninvasive, stool-based RNA technology platform in managing
Crohn’s disease (CD). The data demonstrates the feasibility to
leverage stool-based RNA biomarkers to improve disease monitoring
within inflammatory bowel disease (IBD).
The study, titled "Noninvasive stool RNA test approximates
disease activity in patients with Crohn’s disease," assessed 102
stool samples from 68 individuals, collected over multiple time
points before and after the initiation of advanced therapy. The
test demonstrated 83% sensitivity and 80% specificity in
distinguishing between active disease and remission. Additionally,
a secondary classifier successfully differentiated between mild and
moderate disease severity among those with active disease,
achieving 89% sensitivity and 95% specificity.
“Patients with Crohn’s disease are plagued by unpredictable
periods of remission and relapse, necessitating frequent monitoring
to assess disease activity and response to therapy,” said Erica
Barnell, Chief Medical & Science Officer at Geneoscopy. “Using
RNA biomarkers in stool samples to approximate disease activity in
CD offers a noninvasive and patient-friendly approach that
mitigates the need for physician appointments and uncomfortable
procedures like repeated endoscopies. This study demonstrates that
Geneoscopy’s technology has the potential to change how we manage
and treat CD, enhancing patient outcomes and quality of life.”
CD affects more than 1 million individuals in the U.S.,1 often
leading to serious complications and requiring surgery for up to
80% of patients.2 Maintaining long-term remission is crucial to
effectively avoid complications, surgery, malignancy, and other
side effects.3-5 Despite advancements in treatment options,
accurately evaluating disease severity and predicting therapeutic
outcomes remain challenging. Geneoscopy’s platform has the
potential to deliver more accurate tracking of disease progression,
and provide a cost-effective, convenient way to monitor the
disease, reducing healthcare expenses and overall burden.
About Geneoscopy, Inc.
Geneoscopy Inc. is a life sciences company focused on developing
diagnostic tests for gastrointestinal health. Leveraging its
proprietary, patented stool-derived eukaryotic RNA (seRNA)
biomarker platform, Geneoscopy’s mission is to empower patients and
providers to transform gastrointestinal health through innovative
diagnostics. The company’s FDA-approved ColoSense™ test uses a
proprietary RNA-based platform to screen for colorectal cancer and
advanced adenomas for average-risk individuals over the age of 45.
In partnership with leading universities and biopharmaceutical
companies, Geneoscopy is also developing diagnostic tests for
treatment selection and therapy monitoring in other GI disease
areas. For more information, visit www.geneoscopy.com and follow
the company on LinkedIn.
References:
- Lewis JD, Parlet LE, Funk MLJ, et al. Incidence, Prevalence,
and Racial and Ethnic Distribution of Inflammatory Bowel Disease in
the United States. Gastroenterol. 2023;165:1197-1205.e2.
- Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology
and natural history of inflammatory bowel diseases. Gastroenterol.
2011;140(6):1785-1794.
- Ashton JJ, Green Z, Kolimarala V, Beattie RM. Inflammatory
bowel disease: long-term therapeutic challenges. Expert Rev
Gastroenterol Hepatol. 2019;13(11):1049-1063.
- Gupta N, Bostrom AG, Kirschner BS, et al. Incidence of
stricturing and penetrating complications of Crohn’s disease
diagnosed in pediatric patients. Inflamm Bowel Dis.
2010;16(4):638-644.
- Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses
predict rapid disease progression among children with Crohn’s
disease: immune responses predict disease progression. Am J
Gastroenterol. 2006;101(2):360-367.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240801841402/en/
Geneoscopy Contacts:
Media Andrea Sampson Sampson Public Relations Group
asampson@sampsonprgroup.com
Investor Relations Carrie Mendivil / Ji-Yon Yi Gilmartin Group
investors@geneoscopy.com